Close

Ratings by JPMorgan (Brian Cheng)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
11/10/2022 Clovis Oncology CLVS Downgrade Underweight
(Neutral)
0.98
(0.34)
-65.31% Details
10/28/2022 Zymeworks ZYME Maintain Neutral
(N/A)
 
 
  Details
9/21/2022 Gossamer Bio Inc. GOSS New Coverage Neutral
(N/A)
13.60
(9.02)
-33.68% Details
9/21/2022 Xencor, Inc. XNCR New Coverage Overweight
(N/A)
27.61
(30.86)
11.77% Details
9/21/2022 Intellia Therapeutics NTLA New Coverage Overweight
(N/A)
62.53
(46.12)
-26.24% Details
9/21/2022 ADC Therapeutics ADCT New Coverage Overweight
(N/A)
5.29
(3.62)
-31.57% Details
9/21/2022 Adicet Bio Inc. ACET New Coverage Overweight
(N/A)
14.81
(19.26)
30.05% Details
8/2/2022 Zymeworks ZYME New Coverage Neutral
(N/A)
5.84
(7.58)
29.79% Details
8/2/2022 Protagonist Therapeutics PTGX New Coverage Overweight
(N/A)
9.95
(8.07)
-18.89% Details
8/2/2022 Mersana MRSN New Coverage Neutral
(N/A)
5.07
(7.25)
43% Details
8/2/2022 Editas Medicine EDIT New Coverage Underweight
(N/A)
15.91
(10.25)
-35.58% Details
8/2/2022 Clovis Oncology CLVS New Coverage Neutral
(N/A)
1.67
(0.34)
-79.64% Details
8/2/2022 BioAtla Inc. BCAB New Coverage Overweight
(N/A)
3.40
(10.52)
209.41% Details
8/2/2022 Allogene ALLO New Coverage Neutral
(N/A)
12.98
(9.46)
-27.12% Details